WallStreetZenWallStreetZen

NASDAQ: QNCX
Quince Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for QNCX

Based on 3 analysts offering 12 month price targets for Quince Therapeutics Inc

Min Forecast
$4.00+179.72%
Avg Forecast
$7.67+436.15%
Max Forecast
$10.00+599.3%

Should I buy or sell QNCX stock?

Based on 3 analysts offering ratings for Quince Therapeutics Inc.

Strong Buy
Strong Buy
2 analysts 66.67%
Buy
1 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although QNCX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates QNCX as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their QNCX stock forecasts and price targets.

QNCX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-06-13
lockedlocked$00.00+00.00%2025-03-24
lockedlocked$00.00+00.00%2024-12-18

1 of 1

Forecast return on equity

Is QNCX forecast to generate an efficient return?

Company
-50.16%
Industry
140.91%
Market
90.47%
QNCX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is QNCX forecast to generate an efficient return on assets?

Company
-8.7%
Industry
32.45%
QNCX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

QNCX earnings per share forecast

What is QNCX's earnings per share in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
-$1.06
Avg 2 year Forecast
-$0.85
Avg 3 year Forecast
-$0.72

QNCX revenue forecast

What is QNCX's revenue in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$34.6M
Avg 2 year Forecast
$76.8M
Avg 3 year Forecast
$127.8M

QNCX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
QNCX$1.43$7.67+436.15%Strong Buy
IKNA$1.35N/AN/A
ABOS$1.07$7.50+600.93%Strong Buy
MNOV$1.33$9.00+576.69%Strong Buy
ANRO$2.41$10.67+342.61%Buy
View Top Biotech Stocks

Quince Therapeutics Stock Forecast FAQ

Is Quince Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: QNCX) stock is to Strong Buy QNCX stock.

Out of 3 analysts, 2 (66.67%) are recommending QNCX as a Strong Buy, 1 (33.33%) are recommending QNCX as a Buy, 0 (0%) are recommending QNCX as a Hold, 0 (0%) are recommending QNCX as a Sell, and 0 (0%) are recommending QNCX as a Strong Sell.

If you're new to stock investing, here's how to buy Quince Therapeutics stock.

What is QNCX's earnings growth forecast for 2025-2027?

(NASDAQ: QNCX) Quince Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.33%.

Quince Therapeutics's earnings in 2025 is -$60,709,000.On average, 2 Wall Street analysts forecast QNCX's earnings for 2025 to be -$48,196,909, with the lowest QNCX earnings forecast at -$48,651,597, and the highest QNCX earnings forecast at -$47,742,221. On average, 2 Wall Street analysts forecast QNCX's earnings for 2026 to be -$38,648,465, with the lowest QNCX earnings forecast at -$40,012,528, and the highest QNCX earnings forecast at -$37,284,401.

In 2027, QNCX is forecast to generate -$32,510,179 in earnings, with the lowest earnings forecast at -$42,740,655 and the highest earnings forecast at -$22,279,703.

What is QNCX's revenue growth forecast for 2027-2029?

(NASDAQ: QNCX) Quince Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.

Quince Therapeutics's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast QNCX's revenue for 2027 to be $1,574,629,389, with the lowest QNCX revenue forecast at $822,984,954, and the highest QNCX revenue forecast at $2,326,273,825. On average, 2 Wall Street analysts forecast QNCX's revenue for 2028 to be $3,492,593,552, with the lowest QNCX revenue forecast at $2,328,001,638, and the highest QNCX revenue forecast at $4,657,230,934.

In 2029, QNCX is forecast to generate $5,810,773,933 in revenue, with the lowest revenue forecast at $4,628,722,008 and the highest revenue forecast at $6,992,825,859.

What is QNCX's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: QNCX) forecast ROA is -8.7%, which is lower than the forecast US Biotechnology industry average of 32.45%.

What is QNCX's Price Target?

According to 3 Wall Street analysts that have issued a 1 year QNCX price target, the average QNCX price target is $7.67, with the highest QNCX stock price forecast at $10.00 and the lowest QNCX stock price forecast at $4.00.

On average, Wall Street analysts predict that Quince Therapeutics's share price could reach $7.67 by Jun 13, 2026. The average Quince Therapeutics stock price prediction forecasts a potential upside of 436.15% from the current QNCX share price of $1.43.

What is QNCX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: QNCX) Quince Therapeutics's current Earnings Per Share (EPS) is -$1.39. On average, analysts forecast that QNCX's EPS will be -$1.06 for 2025, with the lowest EPS forecast at -$1.07, and the highest EPS forecast at -$1.05. On average, analysts forecast that QNCX's EPS will be -$0.85 for 2026, with the lowest EPS forecast at -$0.88, and the highest EPS forecast at -$0.82. In 2027, QNCX's EPS is forecast to hit -$0.72 (min: -$0.94, max: -$0.49).

What is QNCX's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: QNCX) forecast ROE is -50.16%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.